Background Growth hormone deficiency is associated with increased morbidity and mortality from cardiovascular diseases, which might be related to changes in glucose and lipid metabolism.
Results Following GHRT, insulin-like growth factor-l (IGF-l) increased significantIy from a basal level 0[75·9 ± 18·9 to 200·8 ± 31·0 p.gL-I after 12 months oftherapy and remained stahle, thereafter. GHRT did nOt affect fasting blood glucose, basal insulin, cholesterol, blood pressure and body weighr. However, at 12 months, HbAlc (6'0 ± 0'1 vs. 5'6 ± 0·1 % at basal, P<O'OS) and triglyceride (2'3 ± 0·4 vs. 1·4 ± 0·3 mmol L-I) significantly increased but returned to pretreatment values at 18 months. Insulin sensitivity was higher in GHD (B'2±3'1) compared to comrols (3·6±O·53xIO-t1 min-I /(p.UmL-1 ), P=0'06) and decreased significamly after 18 months of GHRT to 5·1 ± 2'6, P<0·05. Basal insulin secretion was similar to that in the control group and increased significantly after 12 and 18 months, total insulin secretion only after 12 months. So (glucose effectiveness)was lower in GHD patiems (0'0095 ± 0·001 min-' ) compared to controls (0'020 ± 0·003 min-
Introduction
Growth hormone deficiency (GHD) in adult patients is associated with increased morbidiry and mortaliry from cardiovascular disorders [1] [2] [3] . Hypopituitary patienrs on conventional hormone replaeemem therapy, i.e. hydroeortisone, thyroxine and sex steroids as appropriate, exhibit a nearly doubled mortaliry rate due to cardiovascular diseases [1, 4] , a higher incidence of atherosclerotie plaques in earotid and femoral arteries [5] , and a reduced aortie distensibiliry [6] . Furthermore, smaller hearts [7] and a lower eardiae output [8] have been deseribed. \Vhile the exact mechanism for the inereased morraliry in GHD patients is still undear, changes in lipid metabolism and earbohydrate toleranee might play a major roie. GHD adults are mostly overweight with inereased fat mass predominandy loeated in the abdominal area, aeeompanied by deereased lean body mass, redueed musele strength [9] [10] [11] [12] [13] , elevated plasma total and low densiry lipoprotein (LDL) eholesterol and inereased plasma triglyeerides [14, 15] . Insulin resistance and hyperinsulinaemia have been deseribed in these patients [16] [17] [18] , represenring the eharaeteristie features of the metabolie syndrome [19] . Furthermore, patients eomplain ofimpaired general well-being [20, 21] and bone mineral densiry is redueed [22] .
Growth hormone replacement therapy (GHRT) has been shown to improve well-being, body eomposition and exercise toleranee [23, 24] . The findings on the effeet of GH replaeement on carbohydrate and lipid metabolism, however, are eontroversial. Following short-time GHRT increased fasting glucose [11] , insulin and C-peptide levels have been reporred [23] -preswnably as a compensatory mechanism to insulin resistance, which is seen in GH excess like acromegaly [25, 26] , while others could not confirm these findings [27] . In studies on extended GHRT the decrease in insulin sensitiviry was reversed after 12 and 26 weeks, respectively [17, 28] . \'(fhile an increased insulin secretion suggesting insulin resistance after 3 months of GHRT has been reported recently [17] , the effecr oflong-term GHRTon insulin sensitiviry has not been addressed adequate1y. The present study was undertaken to evaluate the inftuenee of long-term GHRT on carbohydrate metabolism during an 18-month period. Insulin secretion, hepatic insulin extraction and insulin sensitiviry, as weil as glucose effectiveness, were assessed by the minimal model approach employing frequemly sampled intravenous glucose tolerance tests (FSIGT) before and after 12 and 18 months of GHRT. Additionally, these parameters were compared to an adequate control group matched for the degree of obesiry.
Methods

Patients
Eight patients with GHD, seven females/one male; mean age of 46 ± 3 years (range 28-56); mean body mass index (BMI): 31 ±2kgm-2 (range 23-43) entered the study after informed eonsem was obtained. The protoeol was approved by the Human Ethics Committee of the Universiry ofVienna. Patients with a history ofdiabetes, hypertension, or malignancies were excluded. GH deficieney was confirmed by a maximum GH peak iess than 3 p.g L -1 after the intravenous administration of 30 g arginine [29] . GH deficiency was present in each patient for a minimum of 2 years. All patients had additional anterior pituitary defieiencies and were on stable replacement therapy at least 6 months before and during the study period. The c1inical eharacteristies of the eight patients are shown in Table 1 
0·25 U (81p.g) kg-
I per week subcutaneously at 20.00b. Irrespective of body weight the maximum daily dose was not allowed to exceed 4 U. In two patients the rhGH dose had to be reduced because of side-effects due to fluid retention and arthralgias. The lowest dose administered in these patienrs was 0·07 U (22J.tg) kg-I per week.
FSIGT
After an overnight fast a FSIGT was performed at baseline, and then after 12 and 18 months of GHRT. A catheter was inserted imo an antecubital vein for blood sampling and in a contralateral vein for glucose injection. Basal sampies were drawn at -10 and -1 min. At time°glucose (0'3gkg-J body weight) was injected within Imin and additional blood sampies were collected at 2, 4, 6, 8, 10, 12 '5,15,17'5,20,25,30,40,50,60 ,70,80,90,100,110, 120 and 180 min for determination of glucose, insulin and C-peptide.
Data analysis
Data analysis was performed by using the minimal modeiIing technique which, by describing the dynamic relationships between glucose and endogen aus insulin and C-peptide, provides parameters which quantify the main individual factors contributing to glucose tolerance. The structure of the models and the meaning of the parameters have been published in detail elsewhere [30] [31] [32] . The glucose model [30] quantifies the glucose effectiveness, SG, i.e. the effect on glucose disposal per se without dynamic changes in insulin concentration, and the insulin sensitivity index, SI' The C-peptide and insulin models [31] provide the time-courses of glucose-stimulated prehepatic insulin secretion, CPS(t), and that of posthepatic appearance ofthe hormone in periphery, IDR(t). In addition, from C-peptide data, three parameters are estimated which provide the basal insulin release per unit volwne (BSR, pMmin-1 ), and the sensitiviry to glucose ofthe first (cI>l) and second (cI>2) phase of the dynamic (suprabasal) insulin release from the beta cdl. BSR, cl> 1 and 4i2 describe beta cell activiry by factoring out the major components of the prehepatic insulin release: the basal and the dynamic phases.
Calculations
Model parameters were estimated using MINMOD [33, 34] . The total areas under the concentration curves (AUC) of insulin and C-peptide were obtained by integrating with the trapezoidal rule the concentration time-courses from 0 to 180 min. The total amount of insulin secreted per unit volume (TIS) was calculated by integrating CPS(t). The per cent normalized difference between CPS(t) and IDR(t) gave the time-course of hepatic insulin extraction: its integralover 180 min divided by this time interval allowed Glucose metabolism in GH-treated adults 773 the calculation of a weighted mean of the per cent hepatic insulin extraction (HE). The statistical analysis was performed using the Wilcoxon matched pairs signed rank test for differences within the patient group and the non parametric x-test (variance analysis) for differences between the groups. All values are given as means ± SEM. A P-value < 0·05 was considered significant.
Assays
Blood was rapidly centrifuged. Glucose was immediately measured by the glucose oxidase method. Serum for determination of insulin and C-peptide was stored at -20°C and was analysed later by commercially available radioimmunoassays (Insulin: Biodata, Milano, Italy; C-peptide: C-Pep-CT CIS bio international, GIF-SUR-Yvette CEDEX, France). The intra-and interassay coefficients ofvariation for insulin and C-peptide assays were less than 10%. Insulin-like growth factor-l (IGF-I) was measured with a radioimmunoassay method after treannent ofserum with acid ethanol to precipitate and neutralize the IGF-I binding proteins [35] . The minimum detectable IGF-l concentration was 20,ugl-l, the intra-and interassay coefficienrs of variation were 3·1 and 10%, respectiveiy. Haemoglobin Ale (HbAlc) was collected in ethylenediaminetetraacetic acid (EDTA) rubes and determined on a Shimadzu high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoro, Japan). The reference range was 4-6%. The inter-and intra-assay coefficients of variation ranged between 1·2 and 2·6%.
Results
Metabolie profile
All patients were GH deficient as documented by a maximum GH response of less than 3'0,ug L-I to 30 g arginine and a11 patients had at least one additional anterior pituitary deficiency (Table 1) .
IGF-l levels increased significantly after 12 months GHRT from 75·9 ± 18·9~gL-l [0 200·8 ± 31·0~gL-l (P<O·OI). Thereafter, IGF-I plasma concentrations remained stable throughout the study period (195'4:t 23'6,ugL-1 after 18 months; P=O·7 vs. 12 month). IGF-I levels were within 2 standard deviations of those obtained for healthy subjects matched for sex and age. Table 2 shows the metabolie parameters for the controls and patiems before and after 12 and 18 months of GHRT. In summary, BMI, waist-to-hip ratio, fasting blood glucose, basal insulin concentration, cholesterol and blood pressure did not change significamly during GHRT. HbAlc and triglyceride levels increased significantly after 12 months (P<0'05), but were not different from basal levels at 18 months (P=0·15). C-peptide levels were significantly higher after 18 months of GHRT (P<0·02). The control group compared to the GHRT group had Table 3 reports the model-derived parameters_ SI was initially higher in GHD vs_ controls (P= 0-06) but decreased significantly following GHRT after 18 months (P<O-05)_ Glucose effectiveness (Sc) was lower in GHD compared to control at baseline (P<O-OI) and increased after 12 (P<O·05) and 18 months (P<O·03). Basal insulin secretion (BSR) was not different between GHD and controls and increased after 12 months (P<O-OI) and 18 months (P= 0-05), respectively_ Total insulin secretion (TlS) was not different between GHD and controls at basal and increased significantly after 12 months of GHRT. Hepatic insulin extraction was not different berween Table 3 MOOel-eslimaled and calculated parameters from frequemly sampled intravenous glucose lolerance tests for commis and patiems on growth hormone~placememm.erapy GHD and controls and did not change following GHRT. B-cell sensitivities (0 glucose offirsr (4)1) and second phase (4)2) were significandy higher in controls compared (0 the patient group ar basal, bur did not change during 18 months GHRT.
Discussion
In this srudy we could demonstrate elevated insulin sensitiviry in patients with GHD compared (0 BMl-matched control subjects. Leng-term GHRT induced a significanr decrease in insulin sensitivity and an increase in basal and total insulin secretion. Glucose effectiveness, however, improved after 12 and 18 months ofGHRT. These changes were accompanied by a rransient worsening of glycemic control after 12 months, which was reversed at the end of the observation period. All patients in the present study were severely GH deficient as confirmed by a maximum GH response <3p.gL-1 after arginine stimulation. The dose of GHRT was physiological as confirmed by IGF-l levels in the normal range during therapy [35] which does not suggest an iatrogenic GH excess interfering with our results.
In the present study we have employed the FSIGT test to simultaneously evaluate insulin sensitivity, insulin secretion and hepatic insulin extraction. As regards the estimation of insulin sensitiviry this approach has been validated against the glucose clamp method [36] and has been widely used in different nondiabetic populations [37] . Despite their obesity GHD adults displayed a higher degree of insulin sensitiviry when compared to healthy controls matched for the degree of obesity. In fact, when compared with the values for SI obtained by the same method in healthy lean comrols in another srudy [38] , the GHD subjects exhibit a normal degree of insulin sensitivity. The explanation for this finding remains speculative. While the waist-to-hip ratio was not different between the respective groups, systolic blood pressure was significantly higher in controls, however, on average still within the normal range, whereas diastolic blood pressure was not different between the groups. Although hypertension might be associated with insulin resistance, this relatively small difference for systolic blood pressure is very unlikely to be responsible for the pronounced difference in insulin sensitivity. A more likely explanation seems (0 be the absence of GH, which is a potem insulin antagonistic hormone [39] , which could counteract the effect of obesiry on insulin sensitivity in GHD adults. Our finding of increased insulin sensitiviry due to GH deficiency has also been observed by other investigarors [40, 41] . In those studies reporting insulin resistance in GHD subjects [17, 18] , the GHD subjects were more obese than the healthy controls. Thus, the insulin resistance in these patienrs might rather be attributed to obesiry and rat distribution per se than to GH deficiency.
GH excess in acromegalic pariems [25, 26] as weil as experimental short-time GH administration in pharmacological doses in men [42] and in dogs [43] have been shown to induce insulin resistance and hyperinsulinaemia. Most studies investigating glucose metabolism following shorttime GHRT reported either unchanged [27] cr decreased insulin sensirivity [17, 28, 44, 45] . The insulin resistance. however, was mostly reversed following an extended treatment period up to 12 months. In our study, however, longterm GHRT decreased insulin sensitiviry after 12 and 18 months to an extent seen in healthy control subjecrs matched for the degree of obesity. An inadequate high glucocorticoid substitution causing the decrease of insulin sensitivity as a potential explanation is unlikely since the corticotropic-insufficient patients were on a stable cortisol replacement dose before and throughout the study. In addition, it has been reponed. that the bioavailabiliry of orally administered hyclrocortisone is reduced in GHsubstituted patients [46] . Despite our patients becoming insulin resistant they did not exhibit the profile of the metabolie syndrome in terms of hypertension and worsening of lipid metabolism, although a transient increase in triglyceride levels was observed after 12 months.
In nondiabetic subjects insulin resistance is compensated for by hyperinsulinaemia to maintain normal glucose levels. Accordingly, our patients exhibited increased insulin levels in response to decreased insulin sensitiviry at 12 and 18 months following GHRT, which confirms the observation of Salomon et al., who described increased basal insulin levels after 6 months GHRT [23] . The insulin hypersecretion could be divided into its components by the minimal model technique. While basal insulin secretion rate increased significantly after 12 and 18 months, total insulin secretion rate was significantly elevated only at 12 months, whereas hepatic insulin extraction rate remained unchanged. The amount of dynamic first-phase releasable insulin as response to the glucose injection and secondphase insulin release, which represents the capaciry to synthesize newly releasable hormone, remained unchanged after 18 months GHRT, indicating that the basal insulin secretion is responsible for the increase of secreted insulin as also reflected by the elevated basal C-peptide level.
Whether GH per se stimulates insulin secretion, as shown in in viuv studies [47] . andhyperinsulinaemia causes insulin resistance. or decreased insulin sensitiviry causes hyperinsulinism cannot be answered with the minimal model approach. Furthennore. GH-induced changes in protein [48] and lipid metabolism and on body composition [9.23] can influence carbohydrate metabolism. However, no significant increase ofBMI, body fat content and waist-to-hip ratio during GHRT in our patients was observed.
HbAlc was significantly higher in GHD patients at baseline compared wirb obese controls. HbAlc as a measure of glucose control is influenced by insulin sensitiviry as weIl as insulin secretion. While insulin sensitivity was essentially normal in GHD patients, we could observe a decrease in B-cell sensitiviry to glucose of first and second phase in GHD patients, suggesting impaired insulin secretion. Since it is weIl known that GH stimulates insulin secretion [47J GH deficiency might at least in part be responsible for the elevation of the HbA 1c in GHRT patients via impairment of insulin secretion.
The ability to dispose of glucose is dependent on the combined abilities of glucose per se and secreted insulin to stimulate net glucose disposal. As our patients all had adequate beta cell function, the increased insulin secretion in response to insulin resistance could maintain fasting glucose levels and HbAlc levels in reference ranges. Additionally, the observed increase in glucose effectiveness, the importance of which has been reported recently [49] [50] [51] , could be another compensatory mechanism to maintain glucose levels in the physiological range.
In conclusion, when compared to an appropriate BMImatched control group, we could demonstrate increased insulin sensitivity in GHD patients before GHRT which decreased foiiowing GHRT. This was accompanied by insulin hypersecretion and an elevated glucose effectiveness as potential compensatory mechanisms. The induction of insulin resistance by GHRT would be hard to reconcile with the expected benefits of GHRT on overall survival of GH-deficient patients. Thus, further studies on GHreIated effects on other known risk factors for cardiovascular disease and over even longer periods of observation are necessary. \Ve conclude that patients on GHRTwith compromised beta cell function or a family history of diabetes des erve special attention and careful monitoring of glucose metabolism.
